BiotechTube

Ruxolitinib + Navitoclax

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Myelofibrosis (MF)

Conditions

Myelofibrosis (MF)

Trial Timeline

Oct 31, 2017 → Jan 29, 2025

NCT ID
NCT03222609

About Ruxolitinib + Navitoclax

Ruxolitinib + Navitoclax is a phase 2 stage product being developed by AbbVie for Myelofibrosis (MF). The current trial status is completed. This product is registered under clinical trial identifier NCT03222609. Target conditions include Myelofibrosis (MF).

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03222609Phase 2Completed

Competing Products

20 competing products in Myelofibrosis (MF)

See all competitors
ProductCompanyStageHype Score
Ruxolitinib + AbemaciclibEli LillyPhase 1
33
Nusivertib + Ruxolitinib + MomelotinibSumitomo PharmaPhase 1/2
41
ABBV-744 + Navitoclax + RuxolitinibAbbViePhase 1
33
Placebo for Navitoclax + Ruxolitinib + NavitoclaxAbbViePhase 3
77
Mivebresib + Navitoclax + RuxolitinibAbbViePhase 1
33
Navitoclax + VenetoclaxAbbViePre-clinical
23
Navitoclax + Ruxolitinib + Best Available Therapy (BAT)AbbViePhase 3
77
NS-018 + Best Available TherapyNippon ShinyakuPhase 2
52
AZD1480AstraZenecaPhase 1
33
BomedemstatMerckPhase 2
52
Peginterferon alfa-2aMerckPhase 2
52
BomedemstatMerckPhase 1/2
41
MBG453 + NIS793 + Spartalizumab + DecitabineNovartisPhase 1
33
PIM447 + Ruxolitinib + LEE011NovartisPhase 1
33
LDE225 + INC424NovartisPhase 1/2
41
Imatinib mesylateNovartisPhase 2
52
Ruxolitinib + Siremadlin + Crizanlizumab + Sabatolimab + Rineterkib + NIS793NovartisPhase 1/2
41
Ruxolitinib + Ruxolitinib PlaceboNovartisPhase 3
77
RuxolitinibNovartisPre-clinical
23
ruxolitinibNovartisPhase 2
52

Other Products from AbbVie

Pancrelipase + PancrelipaseApproved
85
CREONApproved
85
Venetoclax + AzacitidineApproved
85
Oxybutynin + PlaceboApproved
85
Glecaprevir-pibrentasvirApproved
85